Livia Casciola-Rosen

List of Publications by Year
in descending order

100	7,019	81743	62479
papers	citations	39 h-index	80 g-index

105	105	105	5206
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	<scp>Antiâ€Cortactin</scp> Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis and Rheumatology, 2022, 74, 358-364.	2.9	6
2	Longâ€term extension study of tofacitinib in refractory dermatomyositis. Arthritis and Rheumatology, 2022, 74, 371-372.	2.9	14
3	Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With <scp>Myositisâ€Specific</scp> Autoantibodies. Arthritis and Rheumatology, 2022, 74, 508-517.	2.9	24
4	Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence. Journal of Clinical Investigation, 2022, 132, .	3.9	26
5	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight, 2022, 7, .	2.3	23
6	Presence and Implications of <scp>Antiâ€Angiotensin Converting Enzymeâ€2</scp> Immunoglobulin M Antibodies in <scp>Antiâ€Melanomaâ€Differentiationâ€Associated</scp> 5 Dermatomyositis. ACR Open Rheumatology, 2022, 4, 457-463.	0.9	4
7	Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis. Clinical Reviews in Allergy and Immunology, 2022, 63, 330-341.	2.9	8
8	A Bayesian approach to restricted latent class models for scientifically structured clustering of multivariate binary outcomes. Biometrics, 2021, 77, 1431-1444.	0.8	4
9	Advances at the interface of cancer and systemic sclerosis. Journal of Scleroderma and Related Disorders, 2021, 6, 50-57.	1.0	4
10	Study of Tofacitinib in Refractory Dermatomyositis: An Openâ€Label Pilot Study of Ten Patients. Arthritis and Rheumatology, 2021, 73, 858-865.	2.9	93
11	Granzyme B Induces IRF-3 Phosphorylation through a Perforin-Independent Proteolysis-Dependent Signaling Cascade without Inducing Cell Death. Journal of Immunology, 2021, 206, 335-344.	0.4	6
12	Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective. Journal of the American Academy of Dermatology, 2021, 84, 572-574.	0.6	4
13	Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. Arthritis and Rheumatology, 2021, 73, 315-323.	2.9	19
14	Autoantibodies targeting telomere-associated proteins in systemic sclerosis. Annals of the Rheumatic Diseases, 2021, 80, 912-919.	0.5	19
15	Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection. Arthritis Research and Therapy, 2021, 23, 64.	1.6	9
16	A North American Cohort of Antiâ€SAE Dermatomyositis: Clinical Phenotype, Testing, and Review of Cases. ACR Open Rheumatology, 2021, 3, 287-294.	0.9	28
17	Anti-ANP32A antibodies in systemic sclerosis. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-221354.	0.5	0
18	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14â€“16 December 2018. Neuromuscular Disorders, 2020, 30, 70-92.	0.3	148

#	Article	IF	Citations
19	Myositis Autoantibodies: A Comparison of Results From the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot. Arthritis and Rheumatology, 2020, 72, 192-194.	2.9	34
20	The Autoimmune Myopathies. , 2020, , 703-713.		0
21	Expression of the Autoantigen Topoisomeraseâ€1 is Enriched in the Lung Tissues of Patients With Autoimmune Interstitial Lung Disease: A Case Control Study. ACR Open Rheumatology, 2020, 2, 657-661.	0.9	4
22	Cancer and Scleroderma. Rheumatic Disease Clinics of North America, 2020, 46, 551-564.	0.8	14
23	Antiâ€retinoblastoma Protein Antibodies: A New Specificity in Systemic Lupus Erythematosus Associated With Protection Against Lupus Nephritis. ACR Open Rheumatology, 2019, 1, 287-291.	0.9	2
24	Protective Effect Against Cancer of Antibodies to the LargeÂSubunits of Both <scp>RNA</scp> Polymerases I and <scp>III</scp> in Scleroderma. Arthritis and Rheumatology, 2019, 71, 1571-1579.	2.9	34
25	Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology, 2019, 92, e1416-e1426.	1.5	36
26	4â€…Anti-retinoblastoma protein antibodies are negatively associated with lupus nephritis. , 2019, , .		0
27	Estimating autoantibody signatures to detect autoimmune disease patient subsets. Biostatistics, 2019, 20, 30-47.	0.9	3
28	Antiâ€“<scp>RNPC</scp>â€3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderateâ€toâ€Severe Gastrointestinal Dysmotility. Arthritis Care and Research, 2019, 71, 1164-1170.	1.5	28
29	Distinct dermatomyositis populations are detected with different autoantibody assay platforms. Clinical and Experimental Rheumatology, 2019, 37, 1048-1051.	0.4	12
30	Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-212999.	0.5	60
31	Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement. Seminars in Arthritis and Rheumatism, 2018, 47, 552-556.	1.6	73
32	Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. JAMA Dermatology, 2018, 154, 44.	2.0	32
33	An update on autoantibodies in scleroderma. Current Opinion in Rheumatology, 2018, 30, 548-553.	2.0	21
34	Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis. JAMA Dermatology, 2018, 154, 1199.	2.0	34
35	IFI16 filament formation in salivary epithelial cells shapes the anti-IFI16 immune response in SjÃ¶grenâ€™s syndrome. JCI Insight, 2018, 3, .	2.3	21
36	Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Arthritis Care and Research, 2017, 69, 263-270.	1.5	108

#	Article	IF	Citations
37	Reply. Arthritis Care and Research, 2017, 69, 454-454.	1.5	0
38	Risk of Digital Vascular Events in Scleroderma Patients Who Have Both Anticentromere and Antiâ€“Interferonâ€Inducible Protein 16 Antibodies. Arthritis Care and Research, 2017, 69, 922-926.	1.5	7
39	Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care and Research, 2017, 69, 1771-1776.	1.5	130
40	Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients. Arthritis Care and Research, 2017, 69, 1909-1914.	1.5	95
41	Brief Report: Antiâ€“RNPCâ€3 Antibodies As a Marker of Cancerâ€Associated Scleroderma. Arthritis and Rheumatology, 2017, 69, 1306-1312.	2.9	61
42	More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology, 2017, 56, kew470.	0.9	67
43	Reply. Arthritis and Rheumatology, 2017, 69, 1915-1916.	2.9	0
44	Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality. Arthritis Care and Research, 2017, 69, 1764-1770.	1.5	35
45	Mechanistic and clinical insights at the scleroderma-cancer interface. Journal of Scleroderma and Related Disorders, 2017, 2, 153-159.	1.0	21
46	Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 71-74.	0.4	10
47	Antiâ€“Interferonâ€Inducible Protein 16 Antibodies Associate With Digital Gangrene in Patients With Scleroderma. Arthritis and Rheumatology, 2016, 68, 1262-1271.	2.9	13
48	Enrichment of Scleroderma Vascular Diseaseâ€“Associated Autoantigens in Endothelial Lineage Cells. Arthritis and Rheumatology, 2016, 68, 2540-2549.	2.9	10
49	Association of Antibodies to Interferonâ€Inducible Proteinâ€16 With Markers of More Severe Disease in Primary SjÃ¶gren's Syndrome. Arthritis Care and Research, 2016, 68, 254-260.	1.5	38
50	Ovoid Palatal Patch in Dermatomyositis. JAMA Dermatology, 2016, 152, 1049.	2.0	40
51	Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7526-E7534.	3.3	75
52	Autoantigens as Partners in Initiation and Propagation of Autoimmune Rheumatic Diseases. Annual Review of Immunology, 2016, 34, 395-420.	9.5	49
53	PUF60: a prominent new target of the autoimmune response in dermatomyositis and SjÃ¶gren's syndrome. Annals of the Rheumatic Diseases, 2016, 75, 1145-1151.	0.5	33
54	Spectrum of Muscle Histopathologic Findings in Fortyâ€Two Scleroderma Patients With Weakness. Arthritis Care and Research, 2015, 67, 1416-1425.	1.5	56

#	Article	IF	Citations
55	Molecular Subsetting of Interferon Pathways in SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2015, 67, 2437-2446.	2.9	115
56	Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e172.	3.1	38
57	Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1Î³ antibodies in adults with dermatomyositis. Journal of the American Academy of Dermatology, 2015, 72, 449-455.	0.6	143
58	Examination of Autoantibody Status and Clinical Features Associated With Cancer Risk and Cancerâ€Associated Scleroderma. Arthritis and Rheumatology, 2015, 67, 1053-1061.	2.9	93
59	Review: Cancerâ€Induced Autoimmunity in the Rheumatic Diseases. Arthritis and Rheumatology, 2015, 67, 317-326.	2.9	90
60	Expression of the Dermatomyositis Autoantigen Transcription Intermediary Factor 1Î³ in Regenerating Muscle. Arthritis and Rheumatology, 2015, 67, 266-272.	2.9	42
61	Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma. Clinical and Experimental Rheumatology, 2015, 33, S123-6.	0.4	2
62	Identification of Clinical Features and Autoantibodies Associated With Calcinosis in Dermatomyositis. JAMA Dermatology, 2014, 150, 724.	2.0	96
63	The Autoimmune Myopathies. , 2014, , 547-554.		1
64	Antiâ€“Melanoma Differentiationâ€“Associated Protein 5â€“Associated Dermatomyositis: Expanding the Clinical Spectrum. Arthritis Care and Research, 2013, 65, 1307-1315.	1.5	241
65	Most Patients With Cancerâ€Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXPâ€2 or Transcription Intermediary Factor 1Î³. Arthritis and Rheumatism, 2013, 65, 2954-2962.	6.7	325
66	Myositis autoantibodies. Current Opinion in Rheumatology, 2012, 24, 602-608.	2.0	120
67	A Novel Dermato-Pulmonary Syndrome Associated With MDA-5 Antibodies. Medicine (United States), 2012, 91, 220-228.	0.4	74
68	Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17609-17614.	3.3	140
69	Identification of novel autoantigens by a triangulation approach. Journal of Immunological Methods, 2012, 385, 35-44.	0.6	11
70	Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancerâ€“myositis connection. Arthritis and Rheumatism, 2012, 64, 346-349.	6.7	36
71	Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells. Clinical and Experimental Rheumatology, 2012, 30, 548-53.	0.4	13
72	The lung as a possible target for the immune reaction in myositis. Arthritis Research and Therapy, 2011, 13, 230.	1.6	20

#	Article	IF	Citations
73	The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): AÂretrospective study. Journal of the American Academy of Dermatology, 2011, 65, 25-34.	0.6	476
74	Histidylâ€“transfer RNA synthetase: A key participant in idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2011, 63, 331-333.	6.7	4
75	Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis and Rheumatism, 2010, 62, 2787-2795.	6.7	180
76	Clinical Profile of Anti-PL-12 Autoantibody. Chest, 2009, 135, 1550-1556.	0.4	145
77	Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis and Rheumatism, 2008, 58, 1958-1967.	6.7	119
78	Mechanisms of Disease: autoantigens as clues to the pathogenesis of myositis. Nature Clinical Practice Rheumatology, 2008, 4, 201-209.	3.2	89
79	Mouse and Human Granzyme B Have Distinct Tetrapeptide Specificities and Abilities to Recruit the Bid Pathway. Journal of Biological Chemistry, 2007, 282, 4545-4552.	1.6	93
80	Self-antigen Modification and Autoimmunity. , 2006, , 139-156.		0
81	Stem cells in inflammatory disease. Current Opinion in Rheumatology, 2006, 18, 618-619.	2.0	5
82	Autoimmune myositis: new concepts for disease initiation and propagation. Current Opinion in Rheumatology, 2005, 17, 699-700.	2.0	9
83	Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. Journal of Experimental Medicine, 2005, 201, 591-601.	4.2	351
84	Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: Insights into the association of specific autoantibodies with distinct disease phenotypes. Arthritis and Rheumatism, 2004, 50, 233-241.	6.7	37
85	Centromere protein C is a target of autoantibodies in SjÃ¶gren's syndrome and is uniformly associated with antibodies to Ro and La. Journal of Rheumatology, 2004, 31, 1121-5.	1.0	14
86	Histidylâ€“tRNA Synthetase and Asparaginylâ€“tRNA Synthetase, Autoantigens in Myositis, Activate Chemokine Receptors on T Lymphocytes and Immature Dendritic Cells. Journal of Experimental Medicine, 2002, 196, 781-791.	4.2	246
87	[7] Immunoblotting of single cell types isolated from frozen sections by laser microdissection. Methods in Enzymology, 2002, 356, 70-79.	0.4	4
88	Novel fragments of the Sjï¿½gren's syndrome autoantigens ?-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. Arthritis and Rheumatism, 2001, 44, 2376-2386.	6.7	67
89	Clearing the way to mechanisms of autoimmunity. Nature Medicine, 2001, 7, 664-665.	15.2	85
90	The Inhibition of Apoptosis in Myositis and in Normal Muscle Cells. Journal of Immunology, 2000, 164, 5459-5465.	0.4	93

#	Article	IF	Citations
91	Cleavage by Granzyme B Is Strongly Predictive of Autoantigen Status. Journal of Experimental Medicine, 1999, 190, 815-826.	4.2	477
92	Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death and Differentiation, 1999, 6, 6-12.	5.0	344
93	Granzyme B Directly and Efficiently Cleaves Several Downstream Caspase Substrates: Implications for CTL-Induced Apoptosis. Immunity, 1998, 8, 451-460.	6.6	305
94	Caspase-mediated proteolysis during apoptosis: insights from apoptotic neutrophils. FEBS Letters, 1998, 422, 179-184.	1.3	85
95	Scleroderma Autoantigens Are Uniquely Fragmented by Metal-catalyzed Oxidation Reactions: Implications for Pathogenesis. Journal of Experimental Medicine, 1997, 185, 71-80.	4.2	198
96	Macromolecular substrates for the ICE-like proteases during apoptosis. , 1997, 64, 50-54.		134
97	Macromolecular substrates for the ICE-like proteases during apoptosis. , 1997, 64, 50.		1
98	Sequential activation of three distinct ICE-like activities in Fas-ligated Jurkat cells. FEBS Letters, 1996, 390, 299-303.	1.3	105
99	Autoantigens as Substrates for Apoptotic Proteases: Implications for the Pathogenesis of Systemic Autoimmune Disease. , 0, , 243-260.		0
100	The DNA sensors AIM2 and IFI16 are SLE autoantigens that bind neutrophil extracellular traps. ELife, 0, 11, .	2.8	23